CA3139416A1 - Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer - Google Patents

Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer Download PDF

Info

Publication number
CA3139416A1
CA3139416A1 CA3139416A CA3139416A CA3139416A1 CA 3139416 A1 CA3139416 A1 CA 3139416A1 CA 3139416 A CA3139416 A CA 3139416A CA 3139416 A CA3139416 A CA 3139416A CA 3139416 A1 CA3139416 A1 CA 3139416A1
Authority
CA
Canada
Prior art keywords
treatment
cancer
ephb4
sephb4
refractory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139416A
Other languages
English (en)
French (fr)
Inventor
Valery Krasnoperov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasgene Therapeutics Inc
Original Assignee
Vasgene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasgene Therapeutics Inc filed Critical Vasgene Therapeutics Inc
Publication of CA3139416A1 publication Critical patent/CA3139416A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
CA3139416A 2019-02-13 2020-02-13 Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer Pending CA3139416A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805291P 2019-02-13 2019-02-13
US62/805,291 2019-02-13
PCT/US2020/018160 WO2020168110A1 (en) 2019-02-13 2020-02-13 Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
CA3139416A1 true CA3139416A1 (en) 2020-08-20

Family

ID=72045655

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139416A Pending CA3139416A1 (en) 2019-02-13 2020-02-13 Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer

Country Status (8)

Country Link
US (1) US20220153791A1 (enExample)
EP (1) EP3923969A4 (enExample)
JP (1) JP2022520596A (enExample)
KR (1) KR20220010469A (enExample)
CN (1) CN114007633A (enExample)
AU (1) AU2020221276A1 (enExample)
CA (1) CA3139416A1 (enExample)
WO (1) WO2020168110A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
AU2020241963B2 (en) * 2019-03-17 2026-07-02 Vasgene Therapeutics Inc Treatment of cancers using sEphB4-HSA fusion proteins
CN117120074A (zh) * 2021-03-18 2023-11-24 V·卡拉斯诺佩洛夫 sEphB4-HSA融合蛋白作为癌症治疗的一线疗法的用途
CN118290563B (zh) * 2024-06-03 2024-08-02 磐如生物科技(天津)有限公司 一种前列腺癌抗原肽和免疫佐剂组合物及其在抗肿瘤中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006034455A2 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2012068477A1 (en) * 2010-11-19 2012-05-24 Vasgene Therapeutics, Inc. Methods and compositions for inhibiting angiogenesis and tumor growth
CA2892490A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
AU2020241963B2 (en) * 2019-03-17 2026-07-02 Vasgene Therapeutics Inc Treatment of cancers using sEphB4-HSA fusion proteins

Also Published As

Publication number Publication date
AU2020221276A1 (en) 2021-10-07
WO2020168110A1 (en) 2020-08-20
EP3923969A4 (en) 2022-10-19
JP2022520596A (ja) 2022-03-31
KR20220010469A (ko) 2022-01-25
EP3923969A1 (en) 2021-12-22
CN114007633A (zh) 2022-02-01
US20220153791A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
US20220153791A1 (en) Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer
US11253571B2 (en) Preventive or therapeutic agent for kidney disease
ES2564794T5 (es) R-espondinas como moduladores de angiogénesis y vasculogénesis
EP2870970B1 (en) Prophylactic or therapeutic agent for hepatic diseases
US10786545B2 (en) Use of peptides that block metadherin-SND1 interaction as treatment for cancer
Bähr et al. The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy
Hsu et al. The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
JP2022520285A (ja) 低酸素応答性キメラ抗原受容体
JP7809324B2 (ja) ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療
US10195166B2 (en) Methods for treating hepatitis C virus infectious disease
US20100278810A1 (en) Methods of Modulating Angiogenesis
HK40068256A (en) Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer
Trojan Oncoproteins targeting: antibodies, antisense, triple-helix. Case of anti IGF-I cancer immunogene therapy
US20260053891A1 (en) Methods and compositions for treating cancer
WO2013056255A1 (en) Methods and compositions for inhibiting tumor cell proliferation
JP2016501856A (ja) 乳癌を処置するためのｃｄ４４ｖ６由来ペプチド
Svensson Bioluminescent mouse models of prostate cancer progression and therapy
HK1232431A1 (en) Preventive or therapeutic agent for kidney disease
HK1230518A1 (en) Preventive or therapeutic agent for kidney disease

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260327

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703